search
Back to results

Acupuncture for Diabetic Gastroparesis

Primary Purpose

Diabetic Gastroparesis

Status
Suspended
Phase
Phase 3
Locations
Israel
Study Type
Interventional
Intervention
Acupuncture
placebo/sham acupuncture
Sponsored by
Shaare Zedek Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Gastroparesis focused on measuring diabetes, gastroparesis, acupuncture, symptoms, gastric emptying

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 years and older;
  • Controlled diabetes (<250 mg/dL);
  • Moderate gastroparesis (GCSI > 2.50);
  • Ability to comply with study protocol

Exclusion Criteria:

  • Past experience with acupuncture;
  • History of gastric surgery, intrapyloric botulinum toxin, gastric pacemaker;
  • Uncontrolled diabetes or evidence of diabetic ketoacidosis;
  • Malabsorptive syndrome, liver or pulmonary disease;
  • Pregnancy or fertility treatments;
  • Overt psychopathology.

Sites / Locations

  • The Center for Integrative Complementary Medicine, Shaare Zedek Medical Center
  • Dept. of Gastroenterology, Hadassah University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

A

B

Arm Description

Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)

Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)

Outcomes

Primary Outcome Measures

GCSI score

Secondary Outcome Measures

SF-12 Health Survey Questionnaire; C-13 acetate breath test

Full Information

First Posted
May 7, 2007
Last Updated
December 14, 2008
Sponsor
Shaare Zedek Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00470795
Brief Title
Acupuncture for Diabetic Gastroparesis
Official Title
A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2008
Overall Recruitment Status
Suspended
Why Stopped
Protocol to be re-designed (primary outome still GCSI)
Study Start Date
June 2009 (undefined)
Primary Completion Date
June 2010 (Anticipated)
Study Completion Date
September 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Shaare Zedek Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Gastroparesis is a common complication of prolonged diabetes mellitus, both with Type 1 and Type 2 forms. Treatment of diabetic gastroparesis ranges from changing dietary habits to medications and invasive procedures, all of which offer only partial and transient relief, with some options having potentially harmful effects. Acupuncture is an ancient treatment which has been found to be beneficial for many ailments, including those involving the gastrointestinal tract. We propose to evaluate whether acupuncture is an effective and safe treatment for diabetic gastroparesis using a randomized, double-blind, placebo/sham-controlled crossover trial. Because symptoms of gastroparesis do not correlate well with objective tests of gastric emptying (i.e., scintigraphy or 13C breath tests), our primary outcome value will be the Gastroparesis Cardinal Symptom Index (GCSI), a reliable and validated instrument for quantifying symptoms in these patients. As a secondary outcome we will measure gastric emptying using a C13-acetate breath test, as well as the SF-12 Short Form Health Survey. Blinding of the participants will be evaluated using a Validation of Blinding Questionnaire at the end of the treatment period. Diabetic patients suffering from moderate gastroparesis (total GCSI score > 2.50) who fulfill the inclusion criteria (and none of the exclusion criteria) will be eligible to participate in the study. On induction, participants will fill out the GCSI questionnaire and SF-36 survey, and will undergo a C13-acetate breath test. They will then be randomly assigned to either true acupuncture treatment or placebo/sham acupuncture treatment. Each participant will undergo 8 treatments twice-weekly, for a period of 4 weeks. At the end of the eighth treatment session, each participant will again fill out a GCSI questionnaire and SF-12 form, as well as repeating the C13-acetate breath. Following a 4-week washout period, patients will be crossed over to either placebo/sham or true acupuncture treatment, again 8 twice-weekly treatments, for a period of 4 weeks. At the end of the second treatment regimen all participants will again fill out a GCSI questionnaire and SF-12 form, and undergo a C13-acetate breath test. At the end of the second treatment regimen participants will again fill out a Validation of Blinding Questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Gastroparesis
Keywords
diabetes, gastroparesis, acupuncture, symptoms, gastric emptying

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
Arm Title
B
Arm Type
Placebo Comparator
Arm Description
Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
Intervention Type
Other
Intervention Name(s)
Acupuncture
Intervention Description
acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
Intervention Type
Procedure
Intervention Name(s)
placebo/sham acupuncture
Intervention Description
acupuncture at sham points without skin penetration
Primary Outcome Measure Information:
Title
GCSI score
Time Frame
3 months
Secondary Outcome Measure Information:
Title
SF-12 Health Survey Questionnaire; C-13 acetate breath test
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years and older; Controlled diabetes (<250 mg/dL); Moderate gastroparesis (GCSI > 2.50); Ability to comply with study protocol Exclusion Criteria: Past experience with acupuncture; History of gastric surgery, intrapyloric botulinum toxin, gastric pacemaker; Uncontrolled diabetes or evidence of diabetic ketoacidosis; Malabsorptive syndrome, liver or pulmonary disease; Pregnancy or fertility treatments; Overt psychopathology.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Noah Samuels, M.D.
Organizational Affiliation
Shaare Zedek Medical Center, Jerusalem, Israel
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joseph Lysy, M.D.
Organizational Affiliation
Hadassah University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Center for Integrative Complementary Medicine, Shaare Zedek Medical Center
City
Jerusalem
ZIP/Postal Code
91031
Country
Israel
Facility Name
Dept. of Gastroenterology, Hadassah University Hospital
City
Jerusalem
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Acupuncture for Diabetic Gastroparesis

We'll reach out to this number within 24 hrs